DPP4 and obesity due to melanocortin 4 receptor deficiency: In addition, we also conducted subgroup analyses to investigate subgroup differences in the proportion of mediated effects with respect to sex (male, female), obesity (Body Mass Index < 25, 25 ≤ [kg/m2]) and diabetes status (HbA1c < 7.4, 7.4 ≤ [%]), baseline UACR (<100, 100 ≤ [mg/g Cr]), baseline eGFR (<60, 60 ≤ [mL/min/1.73 m2]), DPP4 inhibitor use (yes, no), and SGLT2 inhibitor use (yes, no).